JP7774349B2 - 三環式ポリペプチド複合体薬物及びその使用 - Google Patents

三環式ポリペプチド複合体薬物及びその使用

Info

Publication number
JP7774349B2
JP7774349B2 JP2024519658A JP2024519658A JP7774349B2 JP 7774349 B2 JP7774349 B2 JP 7774349B2 JP 2024519658 A JP2024519658 A JP 2024519658A JP 2024519658 A JP2024519658 A JP 2024519658A JP 7774349 B2 JP7774349 B2 JP 7774349B2
Authority
JP
Japan
Prior art keywords
compound
test
present
pharmaceutically acceptable
nectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024519658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535472A (ja
Inventor
慧寧 李
建華 夏
志▲ガン▼ 江
海鷹 賀
曙輝 陳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conjustar Zhuhai Biologics Co Ltd
Original Assignee
Conjustar Zhuhai Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjustar Zhuhai Biologics Co Ltd filed Critical Conjustar Zhuhai Biologics Co Ltd
Publication of JP2024535472A publication Critical patent/JP2024535472A/ja
Application granted granted Critical
Publication of JP7774349B2 publication Critical patent/JP7774349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024519658A 2021-09-29 2022-09-23 三環式ポリペプチド複合体薬物及びその使用 Active JP7774349B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111150517.5 2021-09-29
CN202111150517 2021-09-29
CN202111216628 2021-10-19
CN202111216628.1 2021-10-19
PCT/CN2022/120832 WO2023051396A1 (zh) 2021-09-29 2022-09-23 三环多肽偶联药物及其应用

Publications (2)

Publication Number Publication Date
JP2024535472A JP2024535472A (ja) 2024-09-30
JP7774349B2 true JP7774349B2 (ja) 2025-11-21

Family

ID=85781294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519658A Active JP7774349B2 (ja) 2021-09-29 2022-09-23 三環式ポリペプチド複合体薬物及びその使用

Country Status (10)

Country Link
US (1) US12539335B2 (de)
EP (1) EP4393501A4 (de)
JP (1) JP7774349B2 (de)
KR (1) KR20240068062A (de)
CN (1) CN118055772A (de)
AU (1) AU2022356942B2 (de)
CA (1) CA3233035A1 (de)
MX (1) MX2024003876A (de)
WO (1) WO2023051396A1 (de)
ZA (1) ZA202402507B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003876A (es) 2021-09-29 2024-04-19 Conjustar Zhuhai Biologics Co Ltd Conjugado farmaco-polipeptido triciclico y sus aplicaciones.
WO2024222840A1 (zh) * 2023-04-28 2024-10-31 天津星联肽生物科技有限公司 新型放射性核素标记的多肽偶联物及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144654A1 (en) 2015-03-09 2016-09-15 Washington University Inhibitors of growth factor activation enzymes
WO2019243832A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
WO2020264187A1 (en) 2019-06-25 2020-12-30 James Janetka Compounds and methods for treating cancer, viral infections, and allergic conditions
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
WO2021074622A1 (en) 2019-10-15 2021-04-22 Bicycletx Limited Bicyclic peptide ligand drug conjugates
JP2021520378A (ja) 2018-04-04 2021-08-19 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
KR20190085331A (ko) * 2018-01-10 2019-07-18 주식회사 아모센스 조명 장치
WO2020120984A1 (en) * 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
MX2024003876A (es) 2021-09-29 2024-04-19 Conjustar Zhuhai Biologics Co Ltd Conjugado farmaco-polipeptido triciclico y sus aplicaciones.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144654A1 (en) 2015-03-09 2016-09-15 Washington University Inhibitors of growth factor activation enzymes
JP2021520378A (ja) 2018-04-04 2021-08-19 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
WO2019243832A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
WO2019243833A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
WO2020264187A1 (en) 2019-06-25 2020-12-30 James Janetka Compounds and methods for treating cancer, viral infections, and allergic conditions
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
WO2021074622A1 (en) 2019-10-15 2021-04-22 Bicycletx Limited Bicyclic peptide ligand drug conjugates

Also Published As

Publication number Publication date
CA3233035A1 (en) 2023-04-06
US12539335B2 (en) 2026-02-03
AU2022356942B2 (en) 2025-07-03
KR20240068062A (ko) 2024-05-17
CN118055772A (zh) 2024-05-17
ZA202402507B (en) 2024-12-18
JP2024535472A (ja) 2024-09-30
EP4393501A1 (de) 2024-07-03
WO2023051396A1 (zh) 2023-04-06
US20240424120A1 (en) 2024-12-26
EP4393501A4 (de) 2025-12-24
AU2022356942A1 (en) 2024-05-09
MX2024003876A (es) 2024-04-19

Similar Documents

Publication Publication Date Title
US20200237936A1 (en) Fibroblast activation protein (fap)-targeted imaging and therapy
US20250135043A1 (en) DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF
JP7774349B2 (ja) 三環式ポリペプチド複合体薬物及びその使用
CN117015551B (zh) 多肽的制备及其应用
US20240316224A1 (en) Carbonic anhydrase ix targeting agents and methods
WO2013081091A1 (ja) 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
WO2022253051A1 (zh) 多肽偶联药物及其应用
US20250161504A1 (en) Rgd dimer compound, preparation method therefor and use thereof
JP7734891B2 (ja) 新規な構造を有するポリペプチド薬物複合体及びその使用
JP7806238B2 (ja) ステープル含有ポリペプチドおよびその適用
KR20070034064A (ko) 개선된 ｎ4 킬레이트제 결합체
RU2837445C2 (ru) Конъюгированное лекарственное средство на основе трициклического полипептида и его применение
RU2847000C2 (ru) Конъюгат полипептид-лекарственный препарат с новой структурой и его применение
EA051657B1 (ru) Полипептиды, содержащие скрепку, и их применение
HK40095133A (zh) 多肽的制备及其应用
WO2025197823A1 (ja) ペプチド、ペプチド複合体、医薬組成物、細胞培養用組成物、及び医療用、診断用又は研究用に用いられる組成物
WO2023088236A1 (zh) Mt1-mmp的双环肽配体及其缀合物
HK40095133B (zh) 多肽的制备及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251104

R150 Certificate of patent or registration of utility model

Ref document number: 7774349

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150